EUCTR2006-003596-12-GB进行中（未招募）1 期
A neoadjuvant study of chemotherapy versus endocrine therapy in postmenopausal patients with primary breast cancer - NEOCENT
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Histologically proven primary invasive breast cancer which is thought to be suitable for neoadjuvant treatment • T2 tumour or above (ultrasound size >20mm) or any T stage with nodal disease = 20mm diameter on ultrasound assessment • Tumour must be ER positive (patients with ‘ER poor disease’ as defined locally should be excluded. Eligible patients include Allred 6/7/8, H-score =100. • Postmenopausal up to the age of 70 years of age postmenopausal status as defined by: • >12 months since last menstrual period at time of diagnosis OR • postmenopausal gonadotrophin levels (luteinizing hormone or follicle stimulating hormone levels above local criteria) or postmenopausal estradiol levels below local criteria) OR • prior bilateral oophorectomy • (menopause induced by GnRH (gonadotrophin releasing hormone) is not accepted) • Pre-treatment haematology and biochemistry values within acceptable limits: • Hb > 9g/dL • AST/ALT = 1.5 x Upper limit of normal (ULN) • WBC >3.0 x109/l and ANC > 1.5 x 109/l • Platelets > 100 x 109/l • Serum bilirubin <1.5 UNL • Alkaline phosphatase < 1.5 x UNL • Serum creatinine < 1.5 x UNL • WHO Performance Status 0 or 1 • Definite indication for adjuvant chemotherapy • No active, uncontrolled infection • Primary amenable to biopsy • Written informed consent prior to commencement of specific protocol procedures. • No previous malignancy except in the case of basal cell carcinoma or cervical carcinoma in situ, or where the patient has been disease-free for 10 years, and where treatment consisted solely of resection. • No concomitant medical, psychiatric or geographic problems that might prevent completion of treatment or follow-up
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Inflammatory breast cancer • Inoperable disease that is judged very unlikely to be rendered operable by neoadjuvant treatment • ER poor disease as defined locally (e.g: H-score <100, Allred 3/4/5) • Known severe hypersensitivity to aromatase inhibitors. • Any contra-indication to receiving aromatase inhibitors ie clinical evidence or recorded history of osteoporosis • Bilateral invasive breast cancer. • Other serious illness or medical condition: • congestive heart failure or unstable angina pectoris, previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or high-risk uncontrolled arrhythmias • history of significant neurologic or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent • active uncontrolled infection • active peptic ulcer, unstable diabetes mellitus • HRT within 4 weeks of starting treatment • Definite contraindications for the use of corticosteroids. • Any contra-indication to receiving combination anthracycline/taxane chemotherapy • Evidence of distant metastatic disease as disclosed by bone scan, liver and chest imaging. • Only cytological proof of malignancy • Patients not able or willing to give informed consent • Chronic oral treatment with corticosteroids unless initiated > 6 months prior to study entry and at low dose (? 20 mg methylprednisolone or equivalent). • Warfarin or Heparin therapy
研究者
相似试验
尚未招募
2 期
Comparison of chemotherapy before and after definitive chemotherapy-radiotherapy with definitive chemotherapy-radiotherapy alone in patients with advanced cervical cancerIRCT20211011052730N1Shahid Beheshti University of Medical Sciences35
招募中
不适用
Prospective study of neoadjuvant chemotherapy with FEC100x4 for BRCAness cases in triple negative breast cancerBreast cancerJPRN-UMIN000029433Tokyo medical university70
招募中
1 期
Phase I, II study of neoadjuvant chemotherapy with gemcitabine and nab-paclitaxel for resectable pancreatic cancerpancreatic ductal cancerJPRN-jRCTs021200003Ishido Keinosuke30
已完成
不适用
A Prospective Study of Neoadjuvant Chemotherapy with Nivolumab/Gemcitabine/Cisplatin in Muscle-Invasive or Locally-Advanced Urothelial Carcinoma of BladderKCT0003804Samsung Medical Center48
已完成
不适用
Prospective study of neoadjuvant chemotherapy for HER2 positive breast cancer.JPRN-UMIN000046338Sapporo Medical University24